

# HIMSS AsiaPac15

## DIGITAL HEALTHCARE WEEK

6 Sep: CPHIMS Exam • 7-9 Sep: Conference & Exhibition •  
10 Sep: Masterclass Workshops (HL7, ICNP) & Hospital Tour  
Marina Bay Sands, Singapore

Operation   
**BIM**

**SMART Healthcare**  
transforming how we manage health

## *Balancing Immunity : A New Dimension of Healthcare*

By Prof. Dr.Pichaet wiriyachitra  
Ph.D., F.R.A.C.I.

CEO Asian Phytochemicals Public  
Co.,Ltd. (APCO)




**HIMSS AsiaPac15**  
DIGITAL HEALTHCARE WEEK

**HIMSS AsiaPac15 Conference & Exhibition**  
6-10 September 2015, Marina Bay Sands, Singapore

Organised by: **HIMSS** Asia Pacific

Operation



**BIM**

**Prof.Dr.Pichaet wiriyachitra Ph.D., F.R.A.C.I.**  
**Chairman and CEO, Professor**  
**Asian Phytochemicals Public Company Limited**




# *Garcinia mangostana*

**Thai folklore : pericarp for healing wound, curing diarrhea.**




1980




(1)  $R^1 = \text{Me}$  ;  $R^2 = \text{H}$

(3)  $R^1 = R^2 = \text{H}$


(4)  $R^1 = R^2 = \text{Me}$



(2)



(5)



(6)

# 4A ACTIVITIES OF GM-1 FROM MANGOSTEEN

## 1. Antibacterial

MIC 1ppm, equivalent to vancomycin

## 2. Anti-inflammatory/Anti-arthritis

3 times of aspirin efficacy

## 3. Anti-oxidant

better than vitamin E

## 4. Anti-cancer

equivalent to 5-FU



1980 -1984

**In 2007, we announced that  
the health benefit of mangosteen  
is mainly from balancing immunity.**

Operation   
**BIM team**



รศ.ดร.ชญ.เสาวลักษณ์ พงษ์ไพจิตร  
Assoc.Prof.Dr.Souwalak Phongpaichit

รศ.ดร.วิลาวลัย มหาบุษราคัม  
Assoc.Prof.Dr.Wilawan Mahabusarakam

ศ.ดร.พิเชษฐ วิริยะจิตรา  
Prof.Dr.Pichaet Wiriychitra

รศ.ดร.ชญ.อำไพ ปันทอง  
Assoc.Prof.Dr.Ampai Panthong

รศ.ดร.ศิริวรรณ องค์กรไชย  
Assoc.Prof.Dr.Siriwan Ong-chai


**Immunological mode of action of BIM products are  
established by the Biomedical Technology Research  
Center, Chaing Mai University**

# White blood cells are responsible for the balance of immunity

- 1. There are 20 - 55 billions white blood cells in the body**
- 2. These white blood cells communicate with one another through interleukins in a chain reaction manner**


# Types of white blood cells

1. Phagocyte, NK cell and cytotoxic T cell—eliminate foreign pathogens e.g. fungus, bacteria, virus and cancer cells
2. B cell and plasma cell build up antibodies to tackle antigens
3. T helper cells send signals through cytokines to white blood cells in 1 and 2 when there are intruders of pathogens



auto-immunity e.g.

Excessive Th1  $\longrightarrow$  multiple sclerosis, scleroderma  
diabetes type 1



**Excessive** → Allergy, auto-immunity e.g. arthritis, osteoporosis,  
**Th2** oral diseases, liver infection, thyroiditis,  
leukemia, atherosclerosis, asthma, psoriasis,  
uterus inflammation, disrupted sleep etc.

Th Cell



Th17



IL-17, IL-22



Other white blood cells



~~Pathogens~~, ~~fungus~~, ~~bacteria~~, ~~virus~~, ~~cancer~~

Severe conditions of inflammation and

Excessive Th17 → auto-immunity e.g. psoriasis, diabetes type 1, inflamed intestine, arthritis.

T Cell



T reg



IL10



Regulate excessive Th1 Th2 Th17,  
remedying all auto-immune symptoms

**Excessive Treg** → Immunity from Th1 and Th17 will be lowered, cancer cells can escape from the elimination

Balance of immunity  
depends on the balance  
among **Th1, Th2, Th17 and Treg**

# *Th Balance juice*


- **Delicious**
- **No added sugar.**
- **No artificial colour.**
- **No artificial flavour.**
- **No preservatives.**
- **No rind material which may have residual insecticides and liver-toxic content of dark brown tannins.**


**A patent application was filed for the formula.**


Th cells / Treg cells  
of volunteers taking 300 ml. of BIM juice  
before breakfast for 15 days











# The latest results

An improved formulation of *Th Balance Juice*

1 pack (300ml./day) for 15 days

increases the secretion of Interleukin-18 by 50%

Interleukin-18 is Interferon- $\gamma$  inducing factor (IGIF)

involved in Th-1 immune response\*.

\*Biochim Biophys Acta. 2013 Dec;1836(2):296-303

Note : Interleukin-18 is provoked in serum of cancer patients  
treated with 5-fluoro-uracil.

*Th Balance juice* reduces  
all kinds of auto-immunity  
by regulating excessive  
Th1, Th2 and Th17

*Th Balance juice* decreases Th17,  
the ability to eliminate  
cancer cells is reduced.

## However, *Th Balance juice* contains

1. Alpha Hydroxy acid can chelate free ions that promote growth of cancer cells
2. Alpha Hydroxycitric acid traps the enzyme used in the synthesis of fat that is a part of cell-wall lining
3. GM-1 kills cancer cells upon impact
4. Polysaccharides inhibit the spread of cancer cells

**Therefore, *Th Balance juice* is used to slow down the growth of cancer cells in the pathway that is different from balancing immunity**

# Symptoms remedied by *Th Balance juice*

GERD, allergy, auto-immunity e.g. osteoporosis,  
oral diseases, liver infection, thyroiditis,  
leukemia, atherosclerosis, asthma, psoriasis,  
uterus inflammation, disrupted sleep, skin rash,  
multiple sclerosis, scleroderma, etc.


# *Th17 Capsule*

A synergistic mixture of refined extracts from  
Mangosteen, Sesame, Soy, Centella, Guava







# Mangosteen active ingredients




1  
 $\alpha$ -mangostin




2  
 $\gamma$ -mangostin




3  
3-isomangostin



4  
mangostenone D



5: gartanin; R = OH  
6: deoxygartanin; R = H



7: garcinone D; R = CH<sub>3</sub>  
8: garcinone C; R = H


Operation 

**BIM**




# Sesame active ingredients

Sesamin




Sesamol






# Soy active ingredients

Compounds	R <sub>1</sub>	R <sub>2</sub>
Daidzein	H	H
Glycitein	H	OCH <sub>3</sub>
Genistein	OH	H






# Centella active ingredients




Asiaticoside



Madecassoside




# Guava active ingredient




## Th cells / Treg cells

of volunteers taking 2 capsules before  
breakfast and 2 capsules before bedtime  
for 15 days








Th1 increased  
 The ability to eliminate pathogens  
 is improved




Th1

Th1 dominates Th2.  
Allergy is reduced




IL9 (Th9) increases,  
stimulating the ability  
of cytotoxic T-cells to tackle  
cancer cells



Th9

Reference : Oncoimmunology. Mar 1, 2013 ; e 23084



Th17 increases markedly.  
 The ability to eliminate pathogens  
 is improved significantly

Th17

# Th17 cells summon an immune system strike against cancer

The University of Texas M.D. Anderson Cancer Center  
Public release date : 29-Oct-2009

Public release date: 29-Oct-2009  
[ Print | E-mail | Share ] [ Close Window ]



Contact: Scott Merville  
smerville@mdanderson.org  
713-792-0661  
University of Texas M. D. Anderson Cancer Center

## Th17 cells summon an immune system strike against cancer

### Helper T cell's effect raises possibility of cellular therapy, vaccine development

HOUSTON - A specific type of T helper cell awakens the immune system to the stealthy threat of cancer and triggers an attack of killer T cells custom-made to destroy the tumors, scientists from The University of Texas M. D. Anderson Cancer Center report in the early online edition of the journal *Immunity*.

The role of Th17, one of only four known types of T helper cell, opens a possible avenue for overcoming cancer's ability to suppress or hide from the body's immune system, said senior author Chen Dong, Ph.D., professor in M. D. Anderson's Department of Immunology. Dong and colleagues found that Th17 stifled development of metastatic melanoma tumors in the lungs of mice.


"While there is much work to be done, these preclinical findings imply the possibility of taking a patient's Th17 cells, expanding them in the lab, and then re-infusing them as treatment," Dong said. Development of a vaccine to stimulate Th17 cells would be another possible application.

Dong earlier discovered the existence of Th17 cells and established that they secrete the inflammatory protein interleukin-17 (IL-17). His lab showed that overexpression of IL-17 contributes to both autoimmune and inflammatory diseases.

"Th17 cells also are found in a variety of solid tumors and we wanted to know whether these cells promote cancer or play a preventive or protective role," Dong said.

Their research showed that mice made deficient in Th17 cells and then injected with a strain of melanoma that gathers in the lungs experienced aggressive cancer growth compared to mice with normal levels of Th17. At 16 days, tumors in the knockout mice had fused together and coated the lung so extensively that they were no longer countable.

Next, they tested Th17 for preventive effect, injecting Th17 cells primed with tumor-specific antigens and the melanoma cells at the same time. At 16 days, mice with Th17 had low or barely detectable levels of cancer while control mice had a heavy tumor burden in their lungs.



**VIDEO:** Th17 sets off a chain of events that ends with custom-made killer T cells destroying tumors.

[Click here for more information.](#)

A third set of experiments tested a treatment effect, showing that mice injected with Th17 after they already had melanoma in their lungs had a 75 percent reduction in tumor burden compared with normal mice.

In all experiments, mice with Th17 also had higher levels of several categories of immune system cell than did those with normal or suppressed Th17.

T cells are lymphocytes, a type of white blood cell produced by the thymus equipped with receptors that recognize and bind to antigens, pieces of invading organisms presented to the T cells by dendritic cells. The bound antigen converts the T cell to T helper cells that secrete signaling molecules called cytokines to launch an appropriate immune response. Helper cells, in effect, guide the adaptive immune response.

In the *Immunity* paper, additional experiments outlined the specific pathway by which Th17 suppresses tumors:

- Tumor invasion of the lung attracts Th17 cells that secrete IL-17A.
- IL-17A in turn promotes the secretion of two chemokines, CCL2 and CCL20, which recruit leukocytes to the tumor site.
- The leukocytes include dendritic cells, which seize tumor antigens and migrate to the lymph nodes.
- There, the antigens are used to prime CD8+ killer cells, which then migrate to the lung and kill established tumors.

###

The research was funded by grants from the National Institutes of Health, M. D. Anderson's Center for Targeted Therapy, a Leukemia and Lymphoma Society Scholar Award to Dong, and a Trust Fellowship of M. D. Anderson.



**VIDEO:** Cancer manages to suppress or elude the body's immune system to survive and grow. Scientists at The University of Texas M. D. Anderson Cancer Center show this week in...

[Click here for more information.](#)

# Th17 cells summon an immune system strike against cancer

## The University of Texas M.D. Anderson Cancer Center

1. Mice made deficient in **Th17** cell and then injected with a strain melanoma that gathers in the lungs experienced aggressive cancer growth, compared to mice with normal levels of **Th17**.

**2. Mice injected with the melanoma cells and Th17 cells had barely detectable cancer.**

**Th17 prevents cancer !**

3. Mice already had melanoma in the lungs when injected with **Th17** reduced cancer to 25% after 16 days

**Th17 also cures cancer !**

# New findings on Th17 cells cancer treatment protocol

University of Pennsylvania School of Medicine

Published: September 12, 2011

The screenshot shows the New York Times website interface. The main headline is "An Immune System Trained to Kill Cancer". Below the headline is a photograph of a man, likely Dr. Carl June, in a lab coat. The article text is partially visible, starting with "PHILADELPHIA — A year ago, when chemotherapy stopped working against his leukemia, William Ludwig signed up to be the first patient treated in a bold experiment at the University of Pennsylvania. Mr. Ludwig, then 45, a retired corrections officer from Bridgewater, N.J., felt his life draining away and thought he had nothing to lose." The page also features a sidebar with "What's Popular Now" and "Well" section links.

therapy to accomplish something that researchers have hoped to do for decades: train a person's own immune system to kill cancer cells.

Two other patients have undergone the experimental treatment. One had a partial remission: his disease lessened but did not go away completely. Another had a complete remission. All three had had advanced chronic lymphocytic leukemia and had run out of chemotherapy options. Usually, the only hope for a remission in such cases is a bone-marrow transplant, but these patients were not candidates for it.

Dr. Carl June, who led the research and directs translational medicine in the **Abramson Cancer Center at the University of Pennsylvania**, said that the results stunned even him and his colleagues, Dr. David L. Porter, Bruce Levine and Michael Kalos. They had hoped to see some benefit but had not dared dream of complete, prolonged remissions. Indeed, when Mr. Ludwig began running fever, the doctors did not realize at first that it was a sign that his T-cells were engaged in a furious battle with his cancer.

Other experts in the field said the results were a major advance.

"It's great work," said Dr. **Walter J. Urbas** of the Providence Cancer Center and Earle A. Childs Research Institute in Portland, Ore. He called the patients' recoveries remarkable, exciting and significant. "I feel very positive about this new technology. Conceptually, it's very, very big."

Dr. Urbas said he thought the approach would ultimately be used against other types of cancer as well as leukemia and lymphoma. But he cautioned, "For patients today, we're not there yet." And he added the usual scientific caveat: To be considered valid, the results must be repeated in more patients, and by other research teams.

Dr. June called the techniques "a harvest of the information from the molecular biology revolution over the past two decades."

### Hitting a Genetic Jackpot

To make T-cells search out and destroy cancer, researchers must equip them to do several tasks: recognize the cancer, attack it, multiply, and live on inside the patient. A number of research groups have been trying to do this, but the T-cells they engineered could not accomplish all the tasks. As a result, the cells' ability to fight tumors has generally been temporary.

The University of Pennsylvania team seems to have hit all the targets at once. Inside the patients, the T-cells modified by the researchers multiplied to 1,000 to 10,000 times the number infused, wiped out the cancer and then gradually diminished, leaving a population of "memory" cells that can quickly proliferate again if needed.

The researchers said they were not sure which parts of their strategy made it work — special cell-culturing techniques, the use of H.I.V.-1 to carry new genes into the T-cells, or the particular pieces of DNA that they selected to reprogram the T-cells.

The concept of doctoring T-cells genetically was first developed in the 1980s by **Dr. Zeig Eshhar** at the Weizmann Institute of Science in Rehovot, Israel. It involves adding gene sequences from different sources to enable the T-cells to produce what researchers call chimeric antigen receptors, or CARs — protein complexes that transform the cells into, in Dr. June's words, "serial killers."

Mr. Ludwig's disease, chronic lymphocytic leukemia is a cancer of B-cells, the part of the immune system that normally produces antibodies to fight infection. All B-cells, whether healthy or leukemic, have on their surfaces a protein called CD19. To treat patients with the disease, the researchers hoped to reprogram their T-cells to find CD19 and attack B-cells carrying it.

But which gene sequences should be used to reprogram the T-cells, from which sources?

Dr. June said the researchers had hoped to see some benefit but had not dared dream of complete, prolonged remissions. Indeed, when Mr. Ludwig began running fever, the doctors did not realize at first that it was a sign that his T-cells were engaged in a furious battle with his cancer.

Other experts in the field said the results were a major advance.

"It's great work," said Dr. Walter J. Urbas of the Providence Cancer Center and Earle A. Childs Research Institute in Portland, Ore. He called the patients' recoveries remarkable, exciting and significant. "I feel very positive about this new technology. Conceptually, it's very, very big."

Dr. Urbas said he thought the approach would ultimately be used against other types of cancer as well as leukemia and lymphoma. But he cautioned, "For patients today, we're not there yet." And he added the usual scientific caveat: To be considered valid, the results must be repeated in more patients, and by other research teams.

Dr. June called the techniques "a harvest of the information from the molecular biology revolution over the past two decades."

### Hitting a Genetic Jackpot

To make T-cells search out and destroy cancer, researchers must equip them to do several tasks: recognize the cancer, attack it, multiply, and live on inside the patient. A number of research groups have been trying to do this, but the T-cells they engineered could not accomplish all the tasks. As a result, the cells' ability to fight tumors has generally been temporary.

The University of Pennsylvania team seems to have hit all the targets at once. Inside the patients, the T-cells modified by the researchers multiplied to 1,000 to 10,000 times the number infused, wiped out the cancer and then gradually diminished, leaving a population of "memory" cells that can quickly proliferate again if needed.

The researchers said they were not sure which parts of their strategy made it work — special cell-culturing techniques, the use of H.I.V.-1 to carry new genes into the T-cells, or the particular pieces of DNA that they selected to reprogram the T-cells.

The concept of doctoring T-cells genetically was first developed in the 1980s by Dr. Zeig Eshhar at the Weizmann Institute of Science in Rehovot, Israel. It involves adding gene sequences from different sources to enable the T-cells to produce what researchers call chimeric antigen receptors, or CARs — protein complexes that transform the cells into, in Dr. June's words, "serial killers."

Mr. Ludwig's disease, chronic lymphocytic leukemia is a cancer of B-cells, the part of the immune system that normally produces antibodies to fight infection. All B-cells, whether healthy or leukemic, have on their surfaces a protein called CD19. To treat patients with the disease, the researchers hoped to reprogram their T-cells to find CD19 and attack B-cells carrying it.

But which gene sequences should be used to reprogram the T-cells, from which sources?



## **New findings on Th17 cells cancer treatment protocol** **University of Pennsylvania, School of Medicine**

using inert HIV cells to expand T cells (Th1,Th17)  
in the blood outside the body of leukemia patients  
then infusing the blood back to the patients

had cured 2 from 3 patients but with serious side-effects,  
the other patient had partially recovered.

# *Th17 Capsule*

4 capsules a day for 15 days

- Stimulated **Th17** activity by 5 folds.
- Stimulated **Th1** and **Th9** activity by 2 folds.

the ability of NK cells and cytotoxic T-cell  
to eliminate cancer cells is enhanced.

# The regimen for cancer care

Every day

3 *Th17 capsules* are taken

1 hr. before breakfast, lunch and dinner,

promoting **Th17**, **Th1** and **Th9** that

increase the ability to eliminate cancer cells

and

300 ml. *Th Balance juice* is taken 1 hr. after dinner

to increase **Treg** that regulates the body immunity.

With this procedure, the immunity is not only balanced but also dynamic

Operation BIM scientists believe that the dynamic balanced immunity is the key to the effective elimination of cancer cells and have filed an international patent for this procedure

The regimen is particularly recommended for cancer patients with auto-immune symptoms



# Clinical study in Thailand



**Faculty of Medicine, Chiang Mai University**

**By Prof. Dr. Sumitra Thongprasert**

20 terminal stage lung cancer patients who had not responded to chemotherapy and radiotherapy improved their quality of life and lived longer than expected

# Products for End-stage cancer





**Name: Violet Ling Kee Kuang**

**I/C no: 450201085302**

**Address: USJ**

**Age: 63 years**

**Gender: Female**

**Language: Eng/Chinese**

**Tel: 0172769898/0356332292**





**End-stage cancer. (Lung cancer, Bone cancer, Tongue cancer).  
In December 2007, doctor told her to settle all her affairs within  
3 months. Could not walk or talk, saliva dripping all the time,  
very bad cough, tremendous pain in the whole of the body.  
Started using the capsules on the 24 February 2008**

**28 February 2008 (after 4 days)**  
**Got up and sit on the wheel chair by herself.**



d M

**5 March 2008 (after 10 days)**  
**Showed improvement. Pain reduced.**  
**Able to move more. Able to stand up.**



**19 March 2008 (after 24 days)**  
**Able to do some exercise.**  
**Dripping of saliva had become less.**  
**Could talk better.**



## Blood test on 22 April 2008 (after 8 weeks)

**Cancer marker (CEA) was 2 ng/ml. (normal : less than 5ng/ml)**  
**Liver function test showed the liver was in perfect condition.**



# 30 April 2008 (after 9 weeks)

## She could walk by using walker.



**21 May 2008 (after 12 weeks)**  
**Started walking longer distance.**  
**Pain in the body had subsided.**  
**Some pain still remained in the tongue.**



# June 2008

**Could drive a short distance,  
went shopping, taking exercise,  
dining out, beginning to live  
a normal life.**





***Violet Ling Kee Kuang, 23 Oct 2008***


***Last stage cancer***



## Wong Hooi Sooi

- Cancer in nasopharynx in 1994.
- Had operation but no improvement.
- Suffered from flu and pain over the whole body.
- Two years after, CEA index went up to 50 ng/ml.

*(Normal range 0-5 ng/ml.)*



- Went to Singapore for treatment, CEA went down to 1.8 ng/ml. but went up again two months after.
- Cancer metastasized to bones and spinal cord.

**After all the treatments,  
CEA did not drop and stayed at 18 ng/ml.**



**The effect from using Th17 regimen :**  
**After two months, CEA dropped to 3.8**  
**after four months 1.9 ng/ml.,**  
**after six month 1.2 ng/ml.**




**Mr. Wong has continued using the regimen and remained in good health for over 6 years now**

# Liver cancer



- **Dec. 2008 , was admitted in hospital for immediate operation.**
- **The part of liver with cancerous lump of 2.4x1.8x3 cm. was removed. The rest of the liver still had several small lumps.**



- **The Th17 regimen was used continuously for 7 months.**
- **Started gaining weight and keeping the perfect health conditions. No more small lumps was observed.**



- **The 5<sup>th</sup> CT-scan on 2 Aug. 2011, showed no more dark spots in the liver.**
- **AFP 2.54 ng/ml (before the operation, AFP 129 ng/ml)**  
*(normal range – AFP 0-10 ng/ml)*
- **has continued using the regimen and remained in good health for over 6 years now**

# Colon cancer



**Suffered from 3<sup>rd</sup> stage colon cancer**

**Treated with chemotherapy but could not tolerate the side-effects.**

**Th17 capsules were used to relieve the side-effects.**

**The chemotherapy could be continued until the course was completed.**

**No more cancer was detected.**

# Lung cancer



Terminal stage lung cancer, had no positive response from two rounds of chemotherapy.

The doctor expected him to live only for 3 more days.

Started on Th17 regimen on 22 July 2011. The quality of life improved markedly. The size of cancer became smaller.

Continued to live happily for over 2 years until his doctor decided to use him as a subject in the clinical trial of another drug.

# Prostate cancer



Terminal stage prostate cancer treated with radiotherapy without result. cancer metastasized to lymph nodes and spinal cord. Unable to walk

**Quality of life improved markedly and started walking after taking the regimen for 10 months.**

**PSA 100 ng/ml. when start using the regimen**

**PSA 31.88 ng/ml. 3 months after (21/05/2011)**

**PSA 1.86 ng/ml. 5 months after (23/07/2011)**

**PSA 0.82 ng/ml. 8 months after (05/11/2011)**

**Now traveling by BTS with a walking stick**

# Lymp-node cancer



Terminal lymph-node cancer metastasized to thigh bone, causing a large fracture.  
Started using Th17 regimen on 7 May 2011

**After 6 months, no cancer was detected.**

**After 12 months, X-ray showed no more bone fracture.**

**Now, living in perfect health and walking normally**

Some of cancer patients who had  
benefitted from **Th17** regimen



Liver cancer



Skin cancer



Colon cancer



Liver cancer



Colon cancer



Lymphoma



Uterine cancer  
Lump in the breast



Lung cancer



Prostate cancer



Colon cancer



Cervical cancer



Breast cancer



Lung cancer



Breast cancer



Lung cancer



Lukemia



Lung cancer



Breast cancer



Nasopharynx cancer



Thyroid cancer



Breast cancer



Breast cancer



Cervical cancer  
Meta stasis to lung  
and Lymph node

See detail in [www.bim100.com](http://www.bim100.com)

**At this point and time,  
we conclude that **Operation BIM****

**1. Add life to time**

#

**2. Add time to life#**

**3. Create new life#**

# Products for Arthritis




In arthritic patients, Th cells secrete excessive  
**TNF- $\alpha$ , IL6 and IL17**  
causing inflammation and cartilage erosion in joints.

**Th cells / Treg cells**  
**of volunteers taking 2 capsules before**  
**breakfast and 2 capsules before bedtime**  
**for 15 days**




# Arthrinok



# Arthrinok

decreases the secretion of TNF- $\alpha$ , IL-6, IL-17

■ Arthrinok  
■ Placebo



## References :

Immunology and Cell Biology **91**,393-401 (July 2013)

Arthritis Research&Therapy 2006, 8(Suppl 2):S3

American Journal of Pathology Vol167, No.1, July 2005

In addition, the active ingredients of mangosteen, sesame, soy, Centella and guava in the capsule can stimulate the synthesis of cartilage, which acts as a sponge between joints. The symptom keeps improving



# Arthrinok reduced TNF- $\alpha$ , IL-6, IL-17

The severity of inflammation and auto-immune conditions are reduced, e.g. arthritis, SLE, skin-rash, hyperthyroid, Parkinson's, oral cavity inflammation, liver damage, asthma.

# Some of arthritis patients who had benefitted from Arthrinok





Had severe knee pain and could hardly walk. Had scheduled for the knee-cap replacement operation.

**16 June 2010, started using 4X3 Arthrinok capsules and got rid of the pain in 4 days. Then kept decreasing the number of capsules.**

**Has been walking happily up to now without the knee-cap replacement.**





See detail in  
[www.bim100.com](http://www.bim100.com)

# Some of rheumatoid-arthritis patients who had benefitted from Arthrinok



See detail in [www.bim100.com](http://www.bim100.com)

# Some of gout patients who had benefitted from Arthrinok



See detail in  
[www.bim100.com](http://www.bim100.com)

# Some of SLE patients who had benefitted from Arthrinok



See detail in [www.bim100.com](http://www.bim100.com)

# For better results, Arthrinok should be used together with Th Balance Juice

